Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06939257 · ClinicalTrials.gov registry record
The Impact of Gender Affirming Hormone Therapy on Pain In Gender Minority Adults
A clinical trial of Pain and Gender Minority Individuals, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06939257: Recruiting study of Pain and Gender Minority Individuals, sponsored by University of Kansas Medical Center.
NCT06939257 is a study of Pain and Gender Minority Individuals that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 200 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06939257, a study of Pain and Gender Minority Individuals, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.
Primary Outcome
The primary outcome is to measure the presence of chronic pain before and after the initiation of GHT. Participants will be asked if they have had pain on more than half the days of the last 3 months.
Conditions Studied
Study Locations (1)
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2029-09-16 |
What NCT06939257 shows while recruiting
NCT06939257 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (34% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 0 interventions.
NCT06939257 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06939257 about?
NCT06939257 is a clinical study titled "The Impact of Gender Affirming Hormone Therapy on Pain In Gender Minority Adults". TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of ...
What is the current status of trial NCT06939257?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-03-31. Estimated completion is 2029-09-16.
What conditions does trial NCT06939257 study?
This clinical trial studies the following conditions: Pain, Gender Minority Individuals.
Who is sponsoring clinical trial NCT06939257?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06939257 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06939257's enrollment target sits among peer trials
200 87th of 374 higher than 287 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Reliability of Pupil Response to Acute Pain
RECRUITING
-
Pain With Dementia
RECRUITING · NA
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Defense and Veterans Center for Integrative Pain Management (DVCIPM) Pain Registry Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI